Sales Reps hired by Amarin

[Anonymous]

There is no generic Vascepa, Drs must prescribe real thing ...real results=real BIG $$$.I hope you do more DD.

I don't understand your comment. Most drug reps show up at the office and patiently wait for the MD's wife to sign their computer and leave their samples.

I doubt if most established pharma reps spend 60 minutes in an entire week in front of the MD.

Do you think this is accepted behavior in other industry's?

The only ones showing any professional progress, are those that willingly accept risk, these are the actual sales people, who are developing a resume.

what are you?

 

[Anonymous]

Big $$$? More like a big joke. This turd is going already circling the toilet bowl.

Looks the resident idiot AMRN basher is at it again. The biggest turd here is the brainless moron who keeps posting quotes like the one above. Here's another article for you to read that refutes the idiot's groundless opinions once again. Enjoy:

http://finance.yahoo.com/news/bulls-taking-another-shot-amarin-101402312.html

"Bulls taking another shot at Amarin
By David Russell (david.russell@optionmonster.com) | optionMONSTER – 4 hours ago

The bulls keep coming back to Amarin after a jarring selloff last year.

Once considered a takeover candidate, the drug maker gapped lower on Dec. 7 after announcing that it would market its Vascepa cholesterol drug without the benefit of a strategic partner. Management also borrowed at onerous rates to finance the effort.

Friday's option activity indicates that one big investor thinks AMRN is ready to recover all those losses, and then some. optionMONSTER's Heat Seeker scanner detected the purchase of 6,000 June 14 calls for $0.50 and the sale of an equal number of June 20 calls for $0.10. Volume was more than triple the previous open interest at each strike, indicating new positions.

Known as a bullish call spread , the strategy is highly leveraged to gains in the share price. It cost just $0.40 to open and will earn a profit of 1,400 percent if the stock closes at $20 or higher by expiration on June 21.

The relatively inexpensive cost of the trade is its main benefit, giving the investor exposure to a runaway rally while limiting risk in case the stock crashes. (See our Education section for more on how options can be safer than stocks.)

AMRN rose 0.59 percent to $8.58 on Friday. Calls outnumbered puts by a bullish 21-to-1 ratio. More than 20,000 contracts traded in total, compared with fewer than 9,000 in an average session."

 

[Anonymous]

Nothing any Glaxo troll can say will discourage me! Viscera is a GREAT product. We don't have to bash anyone else or get vulgar. We are much too good for that.

 

[Anonymous]

Looks the resident idiot AMRN basher is at it again. The biggest turd here is the brainless moron who keeps posting quotes like the one above. Here's another article for you to read that refutes the idiot's groundless opinions once again. Enjoy:

http://finance.yahoo.com/news/bulls-taking-another-shot-amarin-101402312.html

"Bulls taking another shot at Amarin
By David Russell (david.russell@optionmonster.com) | optionMONSTER – 4 hours ago

The bulls keep coming back to Amarin after a jarring selloff last year.

Once considered a takeover candidate, the drug maker gapped lower on Dec. 7 after announcing that it would market its Vascepa cholesterol drug without the benefit of a strategic partner. Management also borrowed at onerous rates to finance the effort.

Friday's option activity indicates that one big investor thinks AMRN is ready to recover all those losses, and then some. optionMONSTER's Heat Seeker scanner detected the purchase of 6,000 June 14 calls for $0.50 and the sale of an equal number of June 20 calls for $0.10. Volume was more than triple the previous open interest at each strike, indicating new positions.

Known as a bullish call spread , the strategy is highly leveraged to gains in the share price. It cost just $0.40 to open and will earn a profit of 1,400 percent if the stock closes at $20 or higher by expiration on June 21.

The relatively inexpensive cost of the trade is its main benefit, giving the investor exposure to a runaway rally while limiting risk in case the stock crashes. (See our Education section for more on how options can be safer than stocks.)

AMRN rose 0.59 percent to $8.58 on Friday. Calls outnumbered puts by a bullish 21-to-1 ratio. More than 20,000 contracts traded in total, compared with fewer than 9,000 in an average session."

Looking at the Amarin stock pumper. He is flipping out. Take a look at the trading over the last 12 months. I really isn't that much higher than the 52 week low, which tells you that this loser is freaking out after losing money on this turd of an investment.

 

[Anonymous]

Looking at the Amarin stock pumper. He is flipping out. Take a look at the trading over the last 12 months. I really isn't that much higher than the 52 week low, which tells you that this loser is freaking out after losing money on this turd of an investment.

The only turd here is you.

 

[Anonymous]

The only turd here is you.

Look. There is the stock pumper again. Now we know what's talking turd looks like.

 

[Anonymous]

Either you are not a rep, or you are just plain stupid. Hello, McFly........ever hear of IMS weekly data? Apparently not.

2 week lag time. Only 3 weeks into the launch. Do the math

 

[Anonymous]

Perhaps you should take a look at the prescription numbers. From what I have read, it looks like they current average is less than 1 prescription per week per rep for Vascepa.

well yeah, it just launched last week. what would you expect. How many scripts per week did each of your reps get in the first week of product open? It's a small giant and it's doing pretty good, hence the panic and mud-slinging

 

[Anonymous]

I'd have to agree, in that during my interview I was told the salary was 63K, non-negotiable. They are not going to pick off any successful CV reps with 3+ years experience at that price, unless they luck into a great rep who just got laid off.

Perhaps you are one of the lucky bastards that haven't been subjected to layoffs yet (operative word is "yet"). These reps probably did take less than what they were paid before, as you will do too when your number is up. Thank god they were smart enough to have a descent reputation in the industry to strike up the band again and yes, ride the ride till it stops.

If they are really smart they will take any and all opportunities to make bonus and continue to maintain their reputation because I am sure they all know more than you wise-ass what it feels like to be let go from a dying industry, and they will be much more prepared than you if it happens again

 

[Anonymous]

2 week lag time. Only 3 weeks into the launch. Do the math

You can get Earlyview much quicker, moron. Notice the weekly numbers are already being reported. Do a bit of research before you post so that you don't look like a r*****.

 

[Anonymous]

You can get Earlyview much quicker, moron. Notice the weekly numbers are already being reported. Do a bit of research before you post so that you don't look like a r*****.

Earlyview has always been a 2 week lag. Dummy

 

[Anonymous]

Earlyview has always been a 2 week lag. Dummy

Hello, McFly........the weekly numbers HAVE ALREADY BEEN REPORTED. Duh! Every time you post, you look even more ridiculous.

 

[Anonymous]

Hello, McFly........the weekly numbers HAVE ALREADY BEEN REPORTED. Duh! Every time you post, you look even more ridiculous.

Numbers have only been reported to 1/25. That is before reps were in the field!

 

[Anonymous]

Hello, McFly........the weekly numbers HAVE ALREADY BEEN REPORTED. Duh! Every time you post, you look even more ridiculous.

Dear Duh,

You obviously do not work here. You don't know what has or has not been reported concerning sales data. Go back to the GSK board and stay there.
Sincerely,

McFly

 

[Anonymous]

Dear Duh,

You obviously do not work here. You don't know what has or has not been reported concerning sales data. Go back to the GSK board and stay there.
Sincerely,

McFly

Hey moron. The sales data has already been picked up by the media. Can't you read. Duh!!!!!

 

[Anonymous]

Hey moron. The sales data has already been picked up by the media. Can't you read. Duh!!!!!

You may not be aware that IMS data does not reflect all the sales data. Just pointed this fact out. Also, it takes some time to build a launch. Ask about sales numbers in 6, 12 and 18 months, not 3 weeks.

 

[Anonymous]

You may not be aware that IMS data does not reflect all the sales data. Just pointed this fact out. Also, it takes some time to build a launch. Ask about sales numbers in 6, 12 and 18 months, not 3 weeks.

There isn't much missing in the number. Averaging 2 prescriptions per rep is a very poor start.

 

[Anonymous]

There isn't much missing in the number. Averaging 2 prescriptions per rep is a very poor start.

Don't you understand a launch? Don't you understand IMS? You are not in the business are you?
Bet you are an investor. Or a troublemaker from another Pharma co.

 

[Anonymous]

Don't you understand a launch?
I that code word for " I don't know how to sell, unless someone tells me what to do?

 

[Anonymous]

Don't you understand a launch? Don't you understand IMS? You are not in the business are you?
Bet you are an investor. Or a troublemaker from another Pharma co.

I have been in the business much longer than you and can see that this launch is heading for failure. I know that you don't want to hear the truth, but this is reality. You are now seeing why no large pharma company wanted to buy this product/company.